Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
For athletes with diabetes, continuous glucose monitors are game-changers, helping them avoid dangerous blood sugar crashes ...
implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense ® 365 CGM system. Eversense 365 is the ...
Some experts claim that reducing fluctuations throughout the day can help protect against heart disease, even for people who ...
In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.
Senseonics has filed to obtain CE Mark registration for its one-year continuous glucose monitoring (CGM) system, Eversense ...
Fourteen-day continuous glucose monitoring (CGM) traces added to Diabetes Control and Complications Trial (DCCT) data can predict microvascular diabetes complications similarly to glycated hemoglobin.